Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma
| Autor: | Toshiko Toda, Ikuko Ota, Fuminori Taniguchi, Akiko Enatsu, Tasuku Harada, Kazuya Arata |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
medicine.medical_specialty Oral contraceptive pill Visual analogue scale medicine.drug_class Endometriosis Urology Ethinyl Estradiol Contraceptives Oral Hormonal Young Adult Dysmenorrhea Japan Ethinylestradiol medicine Humans Ovarian Diseases Ovarian Reserve Ovarian reserve Pain Measurement Ultrasonography Gynecology Progesterone Congeners business.industry Pelvic pain Ovary Obstetrics and Gynecology Estrogens Drospirenone Organ Size Middle Aged medicine.disease Contraceptives Oral Combined Reproductive Medicine Androstenes Female medicine.symptom business Progestin Biomarkers medicine.drug |
| Zdroj: | European Journal of Obstetrics & Gynecology and Reproductive Biology. 191:116-120 |
| ISSN: | 0301-2115 |
| DOI: | 10.1016/j.ejogrb.2015.06.006 |
| Popis: | Objectives Low dose oral contraceptive pills (OCPs) that contain synthetic estrogen and progestin are often used to relieve chronic pelvic pain associated with endometriosis. We sought to evaluate the efficacy of drospirenone/ethinylestradiol (DRSP/EE) with low-dose estrogen in treating endometrioma. Study design A prospective clinical study in six hospitals and one clinic in Japan was conducted. Forty-nine 23- to 45-year-old patients who suffered from endometriosis-associated dysmenorrhea were included in the study. The primary endpoint was the change in size of ovarian endometrioma as measured by transvaginal ultrasonography. The secondary endpoint was the change in dysmenorrhea as evaluated by VAS (visual analog scale) scores before treatment and at 3 and 6 cycles of treatment. In addition, serum CA125, anti-mullerian hormone (AMH), interleukin (IL)-6, and IL-8 were evaluated after 6 cycles of treatment. Results The maximum diameter and volume of the ovarian endometrioma significantly decreased after 3 and 6 cycles compared with pretreatment. VAS scores of dysmenorrhea pain were also reduced after 1, 3 and 6 cycles. A significant correlation between the reduced size of the endometrioma and the decline of VAS scores was found. The levels of serum CA125 and AMH concentration were decreased after 6 cycles. No significant changes were observed in serum IL-6 and IL-8. Conclusion Low dose DRSP/EE therapy is a promising treatment not only to reduce the size of endometrioma but also for dysmenorrhea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect